Rhythm Pharmaceuticals Inc (RYTM) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Rhythm Pharmaceuticals Inc stock (RYTM) is currently trading at $84.62. Rhythm Pharmaceuticals Inc PS ratio (Price-to-Sales) is 29.72. Analyst consensus price target for RYTM is $137.27. WallStSmart rates RYTM as Sell.
- RYTM PE ratio analysis and historical PE chart
- RYTM PS ratio (Price-to-Sales) history and trend
- RYTM intrinsic value — DCF, Graham Number, EPV models
- RYTM stock price prediction 2025 2026 2027 2028 2029 2030
- RYTM fair value vs current price
- RYTM insider transactions and insider buying
- Is RYTM undervalued or overvalued?
- Rhythm Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- RYTM Piotroski F-Score and Altman Z-Score
- RYTM analyst price target and Smart Rating
Rhythm Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Rhythm Pharmaceuticals Inc (RYTM) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth, institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Rhythm Pharmaceuticals Inc (RYTM) Key Strengths (3)
Revenue surging 36.90% year-over-year
108.92% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Supporting Valuation Data
Rhythm Pharmaceuticals Inc (RYTM) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 29.7x annual revenue
Very expensive at 40.5x book value
Supporting Valuation Data
Rhythm Pharmaceuticals Inc (RYTM) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 3 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 0.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth, Institutional Own., Market Cap. Growth metrics are encouraging with Revenue Growth at 36.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (29.72), Price/Book (40.53) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -90.40%, Operating Margin at -82.20%, Profit Margin at -103.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -90.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 36.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
RYTM Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
RYTM's Price-to-Sales ratio of 29.72x sits near its historical average of 32.03x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 11% below its historical high of 33.47x set in Mar 2026, and 0% above its historical low of 29.72x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Rhythm Pharmaceuticals Inc (RYTM) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Rhythm Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 190M with 37% growth year-over-year. The company is currently unprofitable, posting a -103.6% profit margin.
Key Findings
Revenue growing at 37% YoY, reaching 190M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 22% of revenue (42M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -103.6% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -26M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Rhythm Pharmaceuticals Inc maintain 37%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.15, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Rhythm Pharmaceuticals Inc.
Bottom Line
Rhythm Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 37% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -103.6% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Rhythm Pharmaceuticals Inc(RYTM)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.